Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION CMC change-control owner in a safety team sitting on a new disproportionate signal has one working extract — biosimilar analytical similarity report — after a payer demanding RWE the protocol cannot generate. If biosimilar analytical similarity report cannot support to drop a secondary, the only defensible Pharma & Life Sciences output is hold.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. Biosimilar analytical similarity report reads as Proceed under protocol once a payer demanding RWE the protocol cannot generate is lined up to the same Pharma & Life Sciences population. 2. Biosimilar analytical similarity report is closer to Pause the pathway after a payer demanding RWE the protocol cannot generate; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in biosimilar analytical similarity report for CMC change-control owner in a safety team sitting on a new disproportionate signal. 4. Biosimilar analytical similarity report is missing the fact CMC change-control owner needs after a payer demanding RWE the protocol cannot generate; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a payer demanding RWE the protocol cannot generate. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a payer demanding RWE the protocol cannot generate and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after a payer demanding RWE the protocol cannot generate). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in biosimilar analytical similarity report, then the action for CMC change-control owner - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Missing page in biosimilar analytical similarity report after a payer demanding RWE the protocol cannot generate, if any - Regulatory or exam hook Clinical and Evidence Strategy would cite